Pharmaceutical groups Boehringer Ingelheim and Shire as well as Japanese conglomerate Mitsui’s corporate venturing unit and ATMI have helped Promethera Biosciences, a  Belgium-based cell therapy company, raise €17m ($22.7m).

The companies were joined in the series B round on Wednesday by Belgium-based venture capital firm SambrInvest.

The Walloon Region, which has backed the company since it was founded, has also provided a loan of €6.6m to support its clinical development for its cell therapy product, HepaStem, which is a…